Get started
Author

Laura Rosiñol Dachs

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
2019 · Maria-Victoria Mateos, Joaquin Martinez-Lopez, et al. · Blood · 61
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
2022 · Maria-Victoria Mateos, Joaquín Martínez-López, et al. · Blood · 23
Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma
2018 · Laura Rosinol Dachs, Benjamin Hebraud, et al. · Blood · 22
VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study
2018 · Laura Rosinol Dachs, Albert Oriol, et al. · Blood · 15
Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)
2020 · Maria-Victoria Mateos, Enrique M. Ocio, et al. · Blood · 13
Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes
2019 · Cirino Botta, Cristina Pérez Ruiz, et al. · Blood · 11
S192: Talquetamab (tal) + Daratumumab (dara) in Patients (pts) With Relapsed/refractory Multiple Myeloma (rrmm): Updated Trimm-2 Results
2023 · Nizar J Bahlis, Katja Weisel, et al. · HemaSphere · 9
P879: Long-term Follow-up From Majestec-1 of Teclistamab, a B-cell Maturation Antigen (bcma) X Cd3 Bispecific Antibody, in Patients With Relapsed/refractory Multiple Myeloma (rrmm)
2023 · Surbhi Sidana, Philippe Moreau, et al. · HemaSphere · 8
Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study
2024 · Michel Delforge, Joshua Richter, et al. · Blood · 7
Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
2022 · Noemi Puig, Cristina Agulló, et al. · Blood · 7
Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up
2025 · Saad Usmani, Shaji Kumar, et al. · Blood · 6
PDF
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
2025 · Meletios A Dimopoulos, Meletios A Dimopoulos, et al. · The Lancet Haematology · 6
Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma
2022 · Luis Gerardo Rodríguez-Lobato, Anna de Daniel i Bisbe, et al. · Blood · 6
Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study
2020 · Ola Landgren, Katja Weisel, et al. · Blood · 6
ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
2024 · Cesar Rodriguez, Michal Mielnik, et al. · Blood · 5
P911: Evaluation of Prophylactic Tocilizumab (toci) for the Reduction of Cytokine Release Syndrome (crs) to Inform the Management of Patients (pts) Treated With Teclistamab in Majestec-1
2023 · Niels W.C.J. van de Donk, Alfred Garfall, et al. · HemaSphere · 5
The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?
2018 · Artur Jurczyszyn, Sarah Goldman-Mazur, et al. · Blood · 5
Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study
2024 · Niels W.C.J. van de Donk, Ajai Chari, et al. · Blood · 4
Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites
2024 · Shaji Kumar, Sundar Jagannath, et al. · Blood · 4
Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial
2019 · Noemi Puig, Miguel T Hernández, et al. · Blood · 4
Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis
2024 · Shaji Kumar, Sundar Jagannath, et al. · Blood · 3
Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd
2025 · María-Victoria Mateos, Joaquin Martinez-Lopez, et al. · Blood · 2
PDF
Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
2024 · Jeffrey V Matous, Niels W.C.J. van de Donk, et al. · Blood · 2
Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
2024 · Noemi Puig, Bruno Paiva, et al. · Blood · 2
PDF
Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
2024 · Noemi Puig, Cristina Agullo, et al. · Blood · 2
PDF
Works count: 53
Citation count: 251
H-index: 8
I10-index: 6
Year
Topic
Type